keyword
MENU ▼
Read by QxMD icon Read
search

Lp-PLA2

keyword
https://www.readbyqxmd.com/read/29765452/effects-and-potential-mechanism-of-atorvastatin-treatment-on-lp-pla2-in-rats-with-dyslipidemia
#1
Dongdan Zheng, Anping Cai, Rulin Xu, Zhuocheng Mai, Yingling Zhou, Fanfang Zeng, Liwen Li, Weiyi Mai
Introduction: The effects of statins on lipoprotein-associated phospholipase A2 (Lp-PLA2) are controversial, and the present study aimed to investigate whether atorvastatin could reduce Lp-PLA2 in rats with dyslipidemia. Material and methods: A high-fat and high-cholesterol diet was prescribed to produce a dyslipidemia model. Thereafter, low-dose atorvastatin (5 mg/kg/day), high-dose atorvastatin (20 mg/kg/day) or saline (without-treatment group) was prescribed for 14 days...
April 2018: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/29737567/impact-of-a-non-synonymous-q281r-polymorphism-on-structure-of-human-lipoprotein-associated-phospholipase-a-2-lp-pla-2
#2
Arun B Gurung, Atanu Bhattacharjee
Non-synonymous single nucleotide polymorphisms (nsSNPs) are genetic variations at single base resulting in an amino acid change which have been associated with various complex human diseases. The human Lipoprotein-associated phospholipase A2 (Lp-PLA2 ) gene harbours a rare Q281R polymorphism which was previously reported to cause loss of enzymatic function. Lp-PLA2 is an important enzyme which catalyzes the hydrolysis of polar phospholipids releasing pro-atherogenic and pro-inflammatory mediators involved in the pathogenesis of atherosclerosis...
May 8, 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29715185/darapladib-inhibits-atherosclerosis-development-in-type-2-diabetes-mellitus-sprague-dawley-rat-model
#3
Titin Andri Wihastuti, Teuku Heriansyah, Hanifa Hanifa, Sri Andarini, Zuhrotus Sholichah, Yuni Hendrati Sulfia, Aditya Angela Adam, Jeki Refialdinata, Nurul Cholifah Lutfiana
OBJECTIVE: Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulates inflammation mediators, including intra-cellular adhesion molecule-1 (ICAM-1). Darapladib is known as a Lp-PLA2 specific inhibitor. The aim of this study was to reveal the effect of darapladib on the foam cell number, inducible nitric oxide synthase (iNOS), and ICAM-1 expression in aorta at early stages of the atherosclerosis in type 2 diabetes mellitus Sprague-Dawley rat model...
April 1, 2018: Endocrine Regulations
https://www.readbyqxmd.com/read/29690731/-association-of-serum-lipoprotein-associated-phospholipase-a2-with-vascular-dementia-after-ischemic-stroke
#4
Q L Zhang, P Lu, J W Zhang
Objective: To study the relationship of serum lipoprotein-associated phospholipase A2 (Lp-PLA2) with vascular dementia (VD) after ischemic stroke. Methods: A total of 226 ischemic stroke patients who visited the People's Hospital of Zhengzhou University from June.2013 to Oct.2016 were included and divided into the VD group and the non-dementia group according to the degree of cognitive impairment.The non-dementia group were further divided into the normal cognition group and the vascular cognitive impairment no dementia(VCIND) group...
April 17, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29623345/lp-pla-2-activity-is-associated-with-increased-risk-of-diabetic-retinopathy-a-longitudinal-disease-progression-study
#5
Moneeza K Siddiqui, Gwen Kennedy, Fiona Carr, Alexander S F Doney, Ewan R Pearson, Andrew D Morris, Toby Johnson, Megan M McLaughlin, Rachel E Williams, Colin N A Palmer
AIMS/HYPOTHESIS: The aim of the study was to examine the association between lipoprotein-associated phospholipase A2 (Lp-PLA2 ) activity levels and incident diabetic retinopathy and change in retinopathy grade. METHODS: This was a cohort study of diabetic participants with serum collected at baseline and routinely collected diabetic retinal screening data. Participants with type 2 diabetes from the GoDARTS (Genetics of Diabetes Audit and Research in Tayside Scotland) cohort were used...
April 6, 2018: Diabetologia
https://www.readbyqxmd.com/read/29550277/novel-enzymatic-method-for-assaying-lp-pla-2-in-serum
#6
Saki Yamaura, Shin-Ichi Sakasegawa, Emisa Koguma, Shigeru Ueda, Yuzo Kayamori, Daisuke Sugimori, Ken Karasawa
BACKGROUND: Measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2 ) can be used as an adjunct to traditional cardiovascular risk factors for identifying individuals at higher risk of cardiovascular events. This can be performed by quantification of the protein concentration using an ELISA platform or by measuring Lp-PLA2 activity using platelet-activating factor (PAF) analog as substrate. Here, an enzymatic Lp-PLA2 activity assay method using 1-O-Hexadecyl-2-acetyl-rac-glycero-3-phosphocholine (rac C16 PAF) was developed...
March 14, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29525223/lipoprotein-associated-phospholipase-a%C3%A2-activity-is-increased-in-patients-with-definite-familial-hypercholesterolemia-compared-with-other-forms-of-hypercholesterolemia
#7
A Mattina, D Rosenbaum, R Bittar, D Bonnefont-Rousselot, D Noto, M Averna, E Bruckert, P Giral
BACKGROUND AND AIM: Lipoprotein-associated phospholipase A2 (Lp-PLA2 ) plays a key role in atherosclerosis development. It is considered a marker of increased risk of cardiovascular disease (CVD) and plaque vulnerability. Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol and a higher prevalence of early CVD. Our aim was to evaluate the differences in Lp-PLA2 activity in a population of hypercholesterolemic patients with and without definite FH...
May 2018: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/29525060/usefulness-of-lipoprotein-associated-phospholipase-a-2-activity-and-c-reactive-protein-in-identifying-high-risk-smokers-for-atherosclerotic-cardiovascular-disease-from-the-atherosclerosis-risk-in-communities-study
#8
Martin Tibuakuu, Sina Kianoush, Andrew P DeFilippis, John W McEvoy, Di Zhao, Eliseo Guallar, Christie M Ballantyne, Ron C Hoogeveen, Michael J Blaha, Erin D Michos
Despite the causal role of cigarette smoking in atherosclerotic cardiovascular disease (ASCVD), the underlying mechanisms are not fully understood. We evaluated the joint relation between smoking and inflammatory markers with ASCVD risk. We tested cross-sectional associations of self-reported smoking status (never, former, current) and intensity (packs/day) with lipoprotein-associated phospholipase A2 (Lp-PLA2 ) activity and high-sensitivity C-reactive protein (hsCRP) in 10,506 Atherosclerosis Risk in Communities participants at Visit 4 (1996 to 1998)...
May 1, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29511577/the-relationship-between-lipoprotein-associated-phospholipase-a2-with-cardiovascular-risk-factors-in-testosterone-deficiency
#9
Mustafa Keleşoğlu, Fuat Kızılay, Burcu Barutçuoğlu, Güneş Başol, Fulden Saraç, Işıl Mutaf, Bülent Semerci
Objective: Lipoprotein-associated phospholipase A2 (Lp-PLA2) which is believed to play a role in atherosclerotic inflammatory process due to its function in hydrolysis of phospholipids and release of pro-inflammatory products, is considered as a novel biomarker for vascular risk. In this study we aimed to investigate the alterations in Lp-PLA2 and its relationship with other cardiovascular risk factors in patients with testosterone deficiency. Material and methods: Forty hypogonadic male and 30 healthy male aged between 18-50 years were enrolled in this study...
March 2018: Turkish Journal of Urology
https://www.readbyqxmd.com/read/29464499/catechin-attenuates-coronary-heart-disease-in-a-rat-model-by-inhibiting-inflammation
#10
Su Tu, Feng Xiao, Xiaoyan Min, Huiping Chen, Xiaochun Fan, Kejiang Cao
Accumulating evidence has established that systemic inflammation is an important pathophysiologic factor of coronary heart disease (CHD). In this study, we investigated whether catechin exerts anti-inflammatory function in CHD rats. CHD model of rats was established by high-fat diet feeding and pituitrin injection. The successful building of CHD model was confirmed using blood liquid biochemical analyzer. Additionally, the effects of catechin on CHD parameters and several inflammatory signaling were investigated...
February 20, 2018: Cardiovascular Toxicology
https://www.readbyqxmd.com/read/29442044/microrna-3188-targets-ets-domain-protein-4-and-participates-in-rhoa-rock-pathway-to-regulate-the-development-of-atherosclerosis
#11
Na Li, Jinghong Chen, Jingru Zhao, Tianjun Wang
We aimed to elucidate the roles and regulatory mechanism of miR-3188 in oxidized low-density lipoprotein (ox-LDL)-induced cell injury in THP-1 derived macrophages, thus providing a new insight for the treatment of atherosclerosis (AS). A total of 85 AS patients and 45 healthy controls were enrolled. The levels of miR-3188 and lipoprotein-associated phospholipase A2 (Lp-PLA2) in AS patients and healthy controls were detected. Then ox-LDL was used to treat human THP-1 derived macrophages. The effects of overexpression and suppression of miR-3188 on regulating ox-LDL-induced cell injury in THP-1 derived macrophages were investigated...
November 1, 2017: Die Pharmazie
https://www.readbyqxmd.com/read/29427679/met117-oxidation-leads-to-enhanced-flexibility-of-cardiovascular-biomarker-lipoprotein-associated-phospholipase-a-2-and-reduced-substrate-binding-affinity-with-platelet-activating-factor
#12
Arun Bahadur Gurung, Atanu Bhattacharjee
Human Lipoprotein-associated phospholipase A2 (Lp-PLA2 ) is an important biomarker for cardiovascular diseases and a therapeutically important drug target against Atherosclerosis. It has the ability to hydrolyze various oxidized low density lipoproteins (LDL) and generates potent pro-inflammatory signaling molecules. Both physiological and non-physiological oxidants have been reported to inhibit Lp-PLA2 activity. The mechanism of the enzyme inhibition due to oxidation of surface exposed Met117 at the structural level is not clearly understood...
June 2018: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/29427237/differential-expression-of-lp-pla2-in-obesity-and-type-2-diabetes-and-the-influence-of-lipids
#13
Laura Jackisch, Warunee Kumsaiyai, Jonathan D Moore, Nasser Al-Daghri, Ioannis Kyrou, Thomas M Barber, Harpal Randeva, Sudhesh Kumar, Gyanendra Tripathi, Philip G McTernan
AIMS/HYPOTHESIS: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a circulatory macrophage-derived factor that increases with obesity and leads to a higher risk of cardiovascular disease (CVD). Despite this, its role in adipose tissue and the adipocyte is unknown. Therefore, the aims of this study were to clarify the expression of Lp-PLA2 in relation to different adipose tissue depots and type 2 diabetes, and ascertain whether markers of obesity and type 2 diabetes correlate with circulating Lp-PLA2...
May 2018: Diabetologia
https://www.readbyqxmd.com/read/29424477/association-of-lipoprotein-associated-phospholipase-a2-mass-with-asymptomatic-cerebral-artery-stenosis
#14
Youxin Wang, Bin Zhou, Pingan Zhou, Yan Yao, Qinghua Cui, Yingping Liu, Jichun Yang, Shouling Wu, Xingquan Zhao, Yong Zhou
Cerebral artery stenosis (CAS) is the most important causes of ischaemic stroke. Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays 2 diverse roles in atherosclerosis (pro-inflammatory and anti-inflammatory), and the association between Lp-PLA2 mass and cardiovascular or cerebrovascular events is inconsistent among previous studies. A cross-sectional study including 2012 North Chinese adults aged ≥40 years was performed in 2010-2011 to investigate whether Lp-PLA2 mass is associated with asymptomatic cerebral artery stenosis (ACAS)...
April 2018: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/29390564/the-associations-of-stroke-transient-ischemic-attack-and-or-stroke-related-recurrent-vascular-events-with-lipoprotein-associated-phospholipase-a2-a-systematic-review-and-meta-analysis
#15
REVIEW
Ye Tian, Huan Jia, Sichen Li, Yanmin Wu, Li Guo, Guojun Tan, Bin Li
BACKGROUND: Studies on stroke and lipoprotein-associated phospholipase A2 (Lp-PLA2) have produced conflicting results. OBJECTIVE: The aim of the study was to assess the associations of Lp-PLA2 levels (mass and activity) with recurrent vascular events in patients with transient ischemic attack (TIA) and/or first ischemic stroke and with stroke in the general population. METHODS: The MEDLINE, Embase, the Cochrane Library, Web of Science, Science Direct, China National Knowledge Infrastructure, China Biology Medical Disc (CBMdisc), and WanFang were searched for prospective observational studies reported until January 2017...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29366117/discordantly-elevated-apolipoprotein-b-versus-low-density-lipoprotein-cholesterol-is-associated-with-increased-lp-pla2-activity-and-poorer-outcomes
#16
Jeffrey Meeusen, Leslie Donato, Linnea Baudhuin, Allan Jaffe
No abstract text is available yet for this article.
August 2017: Atherosclerosis
https://www.readbyqxmd.com/read/29336874/regioselectivity-of-thiouracil-alkylation-application-to-optimization-of-darapladib-synthesis
#17
Florian Guibbal, Sébastien Bénard, Jessica Patché, Vincent Meneyrol, Joël Couprie, Jennyfer Yong-Sang, Olivier Meilhac, Emmanuelle Jestin
Darapladib is one of the most potent Lp-PLA2 (Lipoprotein-associated phospholipase A2 ) inhibitor with an IC50 of 0.25 nM. We demonstrate that a crucial step of Darapladib synthesis was not correctly described in the literature, leading to the production of wrong regioisomers. Moreover we show that the inhibitory activity is directly linked to the position on N1 since compounds bearing alkylation on different sites have potentially less interaction within the active site of Lp-PLA2 .
February 15, 2018: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/29332572/lipoprotein-associated-phospholipase-a2-and-coronary-heart-disease
#18
Areti Sofogianni, Stelina Alkagiet, Konstantinos Tziomalos
In the last decades, the role of inflammation in the pathogenesis of atherosclerosis has been the topic of intense research. Several markers of inflammation have shown predictive value for first and recurrent coronary events in patients without and with established coronary heart disease (CHD). Among these markers, lipoprotein-associated phospholipase A2 (Lp-PLA2) has recently received considerable attention. In the present review, the potential role of Lp-PLA2 as a marker of CHD risk and as a therapeutic target is discussed...
January 10, 2018: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29321128/measurement-of-lipoprotein-associated-phospholipase-a2-by-use-of-3-different-methods-exploration-of-discordance-between-elisa-and-activity-assays
#19
Celalettin Topbas, Alan Swick, Morteza Razavi, N Leigh Anderson, Terry W Pearson, Cory Bystrom
BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2 ), an enzyme associated with inflammation, is used as a biomarker for cardiovascular disease risk. Both the concentration and activity of Lp-PLA2 have been shown to be clinically relevant. However, there is a discordance between the serum concentration of Lp-PLA2 measured by the standard ELISA-based immunoassays and the activity of this enzyme, leading to substantial discordance in risk categorization depending on assay format...
April 2018: Clinical Chemistry
https://www.readbyqxmd.com/read/29306475/chronic-inhibition-of-lipoprotein-associated-phospholipase-a-2-does-not-improve-coronary-endothelial-function-a-prospective-randomized-controlled-trial
#20
Megha Prasad, Ryan Lennon, Gregory W Barsness, Abhiram Prasad, Rajiv Gulati, Lilach O Lerman, Amir Lerman
AIMS: Lipoprotein-associated phospholipase A2 (Lp-PLA2 ), a novel biomarker for vascular inflammation, is associated with coronary endothelial dysfunction (CED) and independently predicts cardiovascular events. The current study aimed to determine whether darapladib, an orally administered Lp-PLA2 inhibitor, improved CED. METHODS AND RESULTS: Fifty-four patients with CED were enrolled in a double-blinded randomized placebo-controlled trial, and were randomized to receive oral darapladib, 160mg daily, or placebo...
February 15, 2018: International Journal of Cardiology
keyword
keyword
77751
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"